BR-2302

N/A

Report date: 2025/07/08 10:29:31

Base Information

Drug NameBR-2302
Drug Alias NameBR-2302
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Receptor tyrosine-protein kinase erbB-3Anti-Epidermal growth factor receptor erbB1
TargetsReceptor tyrosine-protein kinase erbB-3Epidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBliss Biopharmaceutical (Hangzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBliss Biopharmaceutical (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A